Results achieved at Steno Diabetes Center Copenhagen

​The starting point for H.C. Hagedorn was research into insulin and its effect and the refinement of insulin. One of the results of this was the development of the first slow-acting insulins in the 1930s.

However, with time the research linked to patient treatment at Steno was separated from the development of new insulin products for commercial use. As a doctor, Hagedorn had developed, with Norman Svendsen, a method for measuring the sugar content of urine.

This was used both to diagnose diabetes and to measure the effect of treatment. Research into better treatment was part of the hospital's activities from the start and has contributed to significant advances for more than 80 years:

  • Mapping of new methods for studying and treating kidney disease.
  • Clarifying the importance of treating blood glucose, blood pressure and lipids (Steno-2 study).
  • Clarifying the importance of hereditary factors in the development of both type 1 and type 2 diabetes.
  • Mapping the role of the immune system in the development of diabetes (xxx study)
  • Clarifying how absorption of insulin from the subcutis can explain the otherwise inexplicable fluctuations in blood glucose from day to day.
  • Mapping of blood glucose and the importance of blood pressure to the development of complications in the small vessels in the eyes and kidneys.
  • Development of methods for early detection and treatment of people with undiagnosed type 2 diabetes.

The results have contributed to improving the quality of treatment at Steno, which has created significant reductions in mortality and the development of complications in the past 10-15 years.

Responsible editor